This round of the GLP-1 weight loss king battle is truly a bloodbath. Pfizer still looks like "I can fight and endure, but the market doesn't believe it." Old Mo Long is also stable, but it's a bit annoying when executives reduce their holdings. Eli Lilly and Novo Nordisk have really become the new energy CP; one's performance exploded to new highs, while the other, despite being picked on by the FDA, held its ground. VKTX soared today, reaching new heights in the cutthroat competition among pharmaceutical growth stocks. Those who didn't get on board are watching the show, those who did are afraid of the high price. Investing in pharmaceuticals really lets you experience what it means to have constant inner drama...